The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Living With HIV: Watch Aaron's Story
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Efavirenz Effects Worse than Reported, Study Says

January 24, 2003

Researchers conducted a study at San Francisco General Hospital that suggests a greater incidence rate of severe psychiatric illness resulting from HIV treatment with efavirenz than had previously been reported. "The serious side effects are suicidal depression including agitation, aggression and hallucinations," said Talia Puzantian, PharmD, an associate clinical professor at the University of California-San Francisco, and a clinical pharmacist in psychiatry at San Francisco General.

Puzantian and colleagues authored a study about efavirenz that was presented at the 40th annual meeting of the Infectious Diseases Society of America (ISDA), in October 2002 in Chicago.

Previous reports had stated that serious efavirenz side effects had less than a 2 percent incidence rate. Puzantian and co-authors questioned the rate after seeing a number of HIV patients on the drug admitted to the psychiatry unit, she said. The investigators undertook a retrospective study of severe psychiatric side effects and central nervous system side effects, comparing a database of HIV patients -- from March 2000 to February 2002 -- who had discontinued efavirenz with a group of patients who had discontinued nelfinavir.

"We wanted to see the numbers in a real-world setting," Puzantian said. "We looked at substance use and psychiatric illness, and the efavirenz and nelfinavir groups were similar, so we controlled for that."

The study found that for HIV patients who had discontinued efavirenz because of side effects, the main problems were psychiatric and CNS side effects, she said. Data showed that 18.3 percent of subjects on efavirenz reported vivid dreams; 14.7 percent complained of insomnia; 10 percent were lethargic or fatigued; 8.3 percent had headaches, and 7.3 percent had dizziness. Of those symptoms among the nelfinavir cohort, the only side effect that was greater than 1.1 percent was fatigue, reported by 7.8 percent. Other CNS effects included nightmares, subjects feeling like they were stoned or had a hangover, and feelings of euphoria, dysphoria, confusion and trouble concentrating.

The most common neuropsychiatric effect was depression, reported by 12 percent of efavirenz subjects and 1.1 percent of nelfinavir subjects. Nelfinavir patients reported no other neuropsychiatric effects, while the efavirenz group reported others including anxiety (9.2 percent), suicidal depression (2.8 percent), hallucinations (1.8 percent) and agitation (1.8 percent).

"Be aware that these psychiatric side effects can occur and probably occur more than we think," Puzantian said. "We can't really guess who it's going to happen to, so we shouldn't assume that if someone doesn't have a substance use or psychiatric illness that it won't occur."

Back to other CDC news for January 24, 2003

Previous Updates

Adapted from:
AIDS Alert

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.